Cancer Vaccines Market
Growth Factors of Cancer Vaccines Market
The cancer vaccines market size was valued at USD 10.12 billion in 2023, and the market is now projected to grow from USD 12.14 billion in 2024 to USD 42.58 billion by 2032, exhibiting a CAGR of 17.0 % during the forecast period of 2024-2032.
The COVID-19 pandemic has affected the cancer vaccines market in a major way, which has underlined the necessity of further and faster development of new vaccines. This devolved resources and focus on COVID-19 vaccines effectively halting cancer vaccine development. But it also created more innovations in vaccine science and cooperative relations between the academia and industry. The Covid-19 revealed to the world the pressing opportunity to fund cancer immunotherapy to provide better quality and effective treatment for patients with tumors. Therefore, users are eagerly awaiting further advancements to take place in the market.
Trends in the cancer vaccines market that has been seen in recent past is increase in personalized and therapeutic vaccines. The development in genomics and proteomics has provided the means of developing vaccines that can be targeted toward individual tumor associated markers. Also, the adaptation of the mRNA technology in its success of COVID-19 focus for higher efficacy and precise mechanisms starts among the new trends. Joint ventures between Biotech companies and research organizations are driving change, and the remedial nature of governmental support is opening up possibilities for clinical trials. Such trends have given rise to what can be called a new optimism in the development of cancer immunotherapy. The above-mentioned factors are driving the cancer vaccines market growth.
Some factors which are driving the market growth include increasing awareness of cancer vaccines and progress in the field of genomic studies, allowing to create vaccines for individual patients. Progress in immunotherapy and growing investment in biotechnology drive change, while favorable political and legal environments enhance clinical trials. Similarly, an increase in the number of cancer patients around the world as well as the need for new solutions also determine market growth. Moreover, increased success in the current experiments of vaccines that have been recently tested and the partnerships between the pharmaceutical firms and research institutions encourage the rate towards more efficient and specific cancer vaccines.
Comprehensive Analysis Cancer Vaccines Market
The market for cancer vaccines has been segmented on the basis of type, technology, indication and distribution. It includes the prophylactic vaccines that target and seek to stop or to slow down cancer formation, and there are the therapeutic vaccines which are used to manage cancers already formed. Some of the technologies used in the development of vaccines include molecular-based, vector-based as well as cell-based technologies which assume distinct methods of vaccine application and effectiveness. Some of the vaccines are developed to treat certain conditions including cervical, bladder, prostate and lung cancer among others. These are available in various forms including packed meals and give access to other distribution channels such as hospitals, government and organizational supply networks and other channels to allow integration to other healthcare systems.
Presently, cancer vaccines market share is dominated by North America. The former is attributed to factors such as, well-developed healthcare systems, R&D expenditure, and higher cancer treatment expenditure. The availability of large number of pharma majors and biotechnology companies coupled with strong regulatory framework strengthens the region’s position. Furthermore, the high incidence of cancer together with a well-developed clinical trial activity in North America proves that new vaccine products are in demand. These factors have cumulative effect towards enabling the region of North America to lead in the global cancer vaccines market.
Key players in this sector include Dendreon Pharmaceuticals LLC. (U.S.), Serum Institute of India Pvt. Ltd. (India), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Walvax Biotechnology Co., Ltd. (China), Synthaverse S.A. (Poland), Center of Molecular Immunology (Cuba), Ferring B.V. (Switzerland), Wantai BioPharm (China)
In 2023, the advanced therapeutic vaccine called BNT11 had been launched, produced by BioNTech as an mRNA vaccine. This innovative product is designed to address a number of cancer-associated antigens at once with the help of mRNA technology that has been used in developing Covid vaccines. BNT111, in this case, is equipped with the capacity of inciting a strong antibody response against several different cancers encoded by specific tumor antigens. Previous clinical trials on Provenge have suggested that early intervention of the drug has produced promising outcomes in treatment and care of cancer patients by offering them the most effective choices. This advance does signal a qualitative shift in cancer immunotherapy.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 17.0% from 2024-2032
Unit Value (USD billion)
Segmentation
By Type
- Preventive
- Therapeutic
By Technology
- Molecular-based
- Vector-based
- Cell-based
By Indication
- Cervical Cancer
- Bladder Cancer
- Prostate Cancer
- Lung Cancer
- Others
By Distribution Channel
- Hospitals
- Government & Organization Supply
- Others
By Region
- North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
- U.S.
- Canada
- France
- Italy
- Spain
- U.K.
- Germany
- Rest of Europe
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Brazil
- Mexico
- Rest of Latin America
- GCC
- South Africa
- Rest of Middle East & Africa)
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Different Cancers, by Key Countries, 2023
- 4.2. Overview of Regulatory Scenario by Key Countries/Regions
- 4.3. Pipeline Analysis, Key Players
- 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
- 4.5. New Product Launches
- 4.6. Impact of COVID-19 on Global Cancer Vaccines Market
- 5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Type
- 5.1.1. Preventive
- 5.1.2. Therapeutic
- 5.2. Market Analysis, Insights and Forecast – By Technology
- 5.2.1. Molecular-based
- 5.2.2. Vector-based
- 5.2.3. Cell-based
- 5.3. Market Analysis, Insights and Forecast – By Indication
- 5.3.1. Cervical Cancer
- 5.3.2. Bladder Cancer
- 5.3.3. Prostate Cancer
- 5.3.4. Lung Cancer
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospitals
- 5.4.2. Government & Organization Supply
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Type
- 6.1.1. Preventive
- 6.1.2. Therapeutic
- 6.2. Market Analysis, Insights and Forecast – By Technology
- 6.2.1. Molecular-based
- 6.2.2. Vector-based
- 6.2.3. Cell-based
- 6.3. Market Analysis, Insights and Forecast – By Indication
- 6.3.1. Cervical Cancer
- 6.3.2. Bladder Cancer
- 6.3.3. Prostate Cancer
- 6.3.4. Lung Cancer
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospitals
- 6.4.2. Government & Organization Supply
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Type
- 7.1.1. Preventive
- 7.1.2. Therapeutic
- 7.2. Market Analysis, Insights and Forecast – By Technology
- 7.2.1. Molecular-based
- 7.2.2. Vector-based
- 7.2.3. Cell-based
- 7.3. Market Analysis, Insights and Forecast – By Indication
- 7.3.1. Cervical Cancer
- 7.3.2. Bladder Cancer
- 7.3.3. Prostate Cancer
- 7.3.4. Lung Cancer
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospitals
- 7.4.2. Government & Organization Supply
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.5.1. France
- 7.5.2. Italy
- 7.5.3. Spain
- 7.5.4. U.K.
- 7.5.5. Germany
- 7.5.6. Rest of Europe
- 8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Type
- 8.1.1. Preventive
- 8.1.2. Therapeutic
- 8.2. Market Analysis, Insights and Forecast – By Technology
- 8.2.1. Molecular-based
- 8.2.2. Vector-based
- 8.2.3. Cell-based
- 8.3. Market Analysis, Insights and Forecast – By Indication
- 8.3.1. Cervical Cancer
- 8.3.2. Bladder Cancer
- 8.3.3. Prostate Cancer
- 8.3.4. Lung Cancer
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospitals
- 8.4.2. Government & Organization Supply
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Type
- 9.1.1. Preventive
- 9.1.2. Therapeutic
- 9.2. Market Analysis, Insights and Forecast – By Technology
- 9.2.1. Molecular-based
- 9.2.2. Vector-based
- 9.2.3. Cell-based
- 9.3. Market Analysis, Insights and Forecast – By Indication
- 9.3.1. Cervical Cancer
- 9.3.2. Bladder Cancer
- 9.3.3. Prostate Cancer
- 9.3.4. Lung Cancer
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospitals
- 9.4.2. Government & Organization Supply
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Type
- 10.1.1. Preventive
- 10.1.2. Therapeutic
- 10.2. Market Analysis, Insights and Forecast – By Technology
- 10.2.1. Molecular-based
- 10.2.2. Vector-based
- 10.2.3. Cell-based
- 10.3. Market Analysis, Insights and Forecast – By Indication
- 10.3.1. Cervical Cancer
- 10.3.2. Bladder Cancer
- 10.3.3. Prostate Cancer
- 10.3.4. Lung Cancer
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospitals
- 10.4.2. Government & Organization Supply
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Dendreon Pharmaceuticals LLC.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Serum Institute of India Pvt. Ltd.
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. GlaxoSmithKline plc
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Walvax Biotechnology Co., Ltd.
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Synthaverse S.A.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Center of Molecular Immunology
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Ferring B.V.
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Wantai BioPharm
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Dynavax Technologies Corporation
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook